Abstract:
BACKGROUND:Esophageal squamous cell carcinoma (ESCC) shows a 5-year survival rate below 10%, demonstrating the urgency in improving its treatment. Alterations in epidermal growth factor receptors are closely related to malignancy transformation in a number of tumors and recent successful targeted therapies have been directed to these molecules. Therefore, in this study, we analyzed the expression of EGFR and HER2 and evaluated EGFR mutation profile as well as the presence of mutations in hotspots of KRAS and BRAF in ESCC patients. METHODS:We performed RT-qPCR, immunohistochemistry and Fluorescent in situ hybridization to determine EGFR and HER2 expression in ESCC patients, and direct sequencing and PCR-RFLP for mutations and polymorphism analysis. RESULTS:Our results showed an increased EGFR mRNA expression in tumors compared to surrounding tissue (p <0.05), with 11% of the cases presenting at least a four-fold difference between tumor and paired adjacent mucosa. EGFR protein overexpression was present only in 4% of the cases. The median expression of HER2 mRNA was not different between tumors and adjacent mucosa. Still, 7% of the tumors presented at least a 25-fold higher expression of this gene when compared to its paired counterpart. Immunohistochemical analysis revealed that 21% of the tumors were positive for HER2 (scores 2+ and 3+), although only 3+ tumors presented amplification of this gene. Mutation analysis for EGFR (exons 18-21), KRAS (codons 12 and 13) and BRAF (V600E) showed no mutations in any of the hotspots of these genes in almost 100 patients analyzed. EGFR presented synonymous polymorphisms at codon 836 (C>T) in 2.1% of the patients, and at codon 787 (G>A) in 79.2% of the cases. This last polymorphism was also evaluated in 304 healthy controls, which presented a similar frequency (73.7%) in comparison with ESCC patients. The absence of mutations of EGFR, KRAS and BRAF as well as the overexpression of EGFR and HER2 in less than 10% of the patients suggest that this signaling pathway is altered in only a small proportion of patients with ESCC. CONCLUSION:HER receptors target therapies may have the potential to be effective in only a minor fraction of patients with ESCC.
journal_name
BMC Cancerjournal_title
BMC cancerauthors
Gonzaga IM,Soares-Lima SC,de Santos PT,Blanco TC,de Reis BS,Quintella DC,de Oliveira IM,de Faria PA,Kruel CD,Andreollo NA,de Simão TA,Pinto LFdoi
10.1186/1471-2407-12-569subject
Has Abstractpub_date
2012-12-04 00:00:00pages
569issn
1471-2407pii
1471-2407-12-569journal_volume
12pub_type
杂志文章相关文献
BMC CANCER文献大全abstract:BACKGROUND:Nonsynonymous mutations change the protein sequences and are frequently subjected to natural selection. The same goes for nonsense mutations that introduce pre-mature stop codons into CDSs (coding sequences). Synonymous mutations, however, are intuitively thought to be functionally silent and evolutionarily ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-5572-x
更新日期:2019-04-16 00:00:00
abstract:BACKGROUND:Leukemia is a cancer of blood and bone marrow cells, causing about 300,000 deaths worldwide. Photodynamic therapy (PDT) is a promising alternative for the treatment of malignant tumors. KillerRed is a genetically encoded red fluorescent protein photosensitizer (PS). In this study, we aimed to investigate the...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-6124-0
更新日期:2019-10-07 00:00:00
abstract:BACKGROUND:Toll-like receptor 3 (TLR3) is a critical component of the innate immune response to dsRNA viruses, which was considered to be mainly expressed in immune cells and some endothelial cells. In this study, we investigated the expression and proapoptotic activity of TLR3 in human and murine tumor cell lines. ME...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-8-12
更新日期:2008-01-17 00:00:00
abstract:BACKGROUND:Durvalumab is a standard drug used during maintenance therapy after chemoradiotherapy in patients with locally advanced non-small cell lung cancer (LA-NSCLC). However, little is known about the clinical benefits of durvalumab after chemoradiotherapy in patients with LA-NSCLC with a performance status (PS) of...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-07406-y
更新日期:2020-10-06 00:00:00
abstract:BACKGROUND:Ovarian cancer is the leading cause of death among gynecologic diseases in Western countries. We have previously identified a miR-200-E-cadherin axis that plays an important role in ovarian inclusion cyst formation and tumor invasion. The purpose of this study was to determine if the miR-200 pathway is invol...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3417-z
更新日期:2017-06-17 00:00:00
abstract:BACKGROUND:The expression of a neural crest stem cell marker, polysialic acid (polySia), and its main carrier, neural cell adhesion molecule (NCAM), have been detected in some malignant tumors with high metastatic activity and unfavorable prognosis, but the diagnostic and prognostic value of polySia-NCAM in neuroblasto...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-9-57
更新日期:2009-02-17 00:00:00
abstract:BACKGROUND:Recently, a phase II clinical trial in hepatocellular carcinoma (HCC) has suggested that the combination of sorafenib and 5-fluorouracil (5-FU) is feasible and side effects are manageable. However, preclinical experimental data explaining the interaction mechanism(s) are lacking. Our objective is to investig...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-363
更新日期:2013-07-29 00:00:00
abstract:BACKGROUND:CD133 (prominin-1) is widely believed to be a cancer stem cell marker in various solid tumor types, and CD133 has been correlated with tumor-initiating capacity. Recently, the nuclear location of CD133 expression in tumors has been discussed, but hepatocellular carcinoma (HCC) has not been included in these ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-017-3460-9
更新日期:2017-07-07 00:00:00
abstract:BACKGROUND:Expression of Nodal, a member of the TGF-β superfamily, is commonly absent in differentiated tissues, while its re-expression occurs in a variety of human malignancy. However, little is known about its involvement in ovarian tumorigenesis. Herein, we focused on the functional roles of Nodal in ovarian endome...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-019-5539-y
更新日期:2019-04-03 00:00:00
abstract:BACKGROUND:Although combination chemotherapy (CC) is generally recommended in recurrent or primary metastatic gastric cancer (RPMGC), the results of randomized trials are conflicting. METHODS:A retrospective review was conducted on 687 RPMGC patients who received palliative chemotherapy. We compared the overall surviv...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-6666-1
更新日期:2020-03-02 00:00:00
abstract:BACKGROUND:Recent randomized controlled trials comparing neoadjuvant chemoradiation plus surgery or perioperative chemotherapy plus surgery with surgery alone showed significant survival benefits for combined modality treatment of patients with localized esophageal adenocarcinoma. However, head-to-head comparisons of n...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/s12885-016-2564-y
更新日期:2016-07-19 00:00:00
abstract:BACKGROUND:High resolution anoscopy (HRA) examination is regarded as the best method for the management of anal high grade squamous intraepithelial lesions to prevent anal squamous carcinoma. However, little is known about the acceptability of this procedure. This analysis looks at patient experience of HRA examination...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4475-6
更新日期:2018-05-11 00:00:00
abstract:BACKGROUND:Hepatocellular carcinoma (HCC) represents a highly vascularized tumor entity and the process of angiogenesis is essential for the growth of HCC. Importantly, the pro-angiogenic transcription factors HIF-1alpha and STAT3 have been implicated in HCC progression, thus representing interesting targets for molecu...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-8-206
更新日期:2008-07-23 00:00:00
abstract:BACKGROUND:Aquaporins (AQPs) have been recognized to promote tumor progression, invasion, and metastasis and are therefore recognized as promising targets for novel anti-cancer therapies. Potentially relevant AQPs in distinct cancer entities can be determined by a comprehensive expression analysis of the 13 human AQPs....
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-161
更新日期:2011-05-06 00:00:00
abstract:BACKGROUND:Alterations in the redox balance are involved in the origin, promotion and progression of cancer. Inter-individual differences in the oxidative stress regulation can explain a part of the variability in cancer susceptibility.The aim of this study was to evaluate if polymorphisms in genes codifying for the di...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-861
更新日期:2014-11-21 00:00:00
abstract:BACKGROUND:CD26/dipeptidyl peptidase IV (DPPIV) is a multifunctional membrane protein with a key role in T-cell biology and also serves as a marker of aggressive cancers, including T-cell malignancies. METHODS:Versican expression was measured by real-time RT-PCR and Western blots. Gene silencing of versican in parenta...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-13-517
更新日期:2013-11-01 00:00:00
abstract:BACKGROUND:Analysis of the clinical response of extramedullary lesions in leukemic patients treated with radiation therapy (RT) and defining the optimal dose of radiation. METHODS:Forty-two extramedullary lesions found in 24 leukemic patients treated with RT were reviewed. The radiation was delivered usually 2 Gy/day,...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-11-428
更新日期:2011-10-06 00:00:00
abstract:BACKGROUND:Estrogen receptor positive breast cancers have high recurrence rates despite tamoxifen therapy. Breast cancer stem/progenitor cells (BCSCs) initiate tumors, but expression of estrogen (ER) or progesterone receptors (PR) and response to tamoxifen is unknown. Interleukin-6 (IL-6) and interleukin-8 (IL-8) may i...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-14-733
更新日期:2014-09-30 00:00:00
abstract:BACKGROUND:Studies have consistently indicated that the majority of individuals meeting the US Prevention Services Task Force guidelines for genetic testing have not had genetic counseling or testing. Despite increased availability and lower costs of multiplex cancer gene panels, there remains a gap in genetics service...
journal_title:BMC cancer
pub_type: 杂志文章,随机对照试验
doi:10.1186/s12885-019-5868-x
更新日期:2019-07-02 00:00:00
abstract:BACKGROUND:The cholesterol biosynthesis pathway is typically upregulated in breast cancer. The role of NAD(P)-dependent steroid dehydrogenase-like (NSDHL) gene, which is involved in cholesterol biosynthesis, in breast cancer remains unknown. This study aimed to uncover the role of NSDHL in the growth and metastasis of ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-020-06840-2
更新日期:2020-05-04 00:00:00
abstract:: ...
journal_title:BMC cancer
pub_type: 社论,历史文章
doi:10.1186/s12885-018-5020-3
更新日期:2018-11-12 00:00:00
abstract::It has been highlighted that in the original manuscript [1] Table S3 'An example of the predictive computational modeling process. Specific details on an annexure section of the PD-L1 pathway show the step-by-step reactions, mechanisms, and reaction equations that occur. Such reactions also occurred in all of the othe...
journal_title:BMC cancer
pub_type: 杂志文章,已发布勘误
doi:10.1186/s12885-018-4200-5
更新日期:2018-04-12 00:00:00
abstract:BACKGROUND:The use of chemotherapy regimens with moderate or high risk of febrile neutropenia (defined as having a FN incidence of 10% or more) and the respective incidence and clinical management of FN in breast cancer and NHL has not been studied in Belgium. The existence of a medical need for G-CSF primary and secon...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究
doi:10.1186/1471-2407-10-642
更新日期:2010-11-23 00:00:00
abstract:BACKGROUND:Shared decision-making (SDM) is recommended for men facing prostate cancer (PC) screening decisions. We synthesize the evidence on the comparative effectiveness of SDM with usual care. METHODS:We searched academic and grey literature databases, and other sources for primary randomised controlled trials (RCT...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4794-7
更新日期:2018-10-22 00:00:00
abstract:BACKGROUND:The management of unresectable or metastatic gastrointestinal stromal tumors (GISTs) has previously been difficult as they are resistant to conventional chemotherapy and radiation. The development of imatinib mesylate has made a major impact on the management of advanced GISTs. It is apparent that there are ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/1471-2407-4-74
更新日期:2004-10-09 00:00:00
abstract:BACKGROUND:Obesity is associated with tumor aggressiveness and disease-specific mortality for more than 15 defined malignancies, including prostate cancer. Preclinical studies suggest that weight loss from caloric restriction and increased physical activity may suppress hormonal, energy-sensing, and inflammatory factor...
journal_title:BMC cancer
pub_type: 杂志文章,随机对照试验
doi:10.1186/s12885-016-2075-x
更新日期:2016-02-05 00:00:00
abstract:BACKGROUND:An emerging immunotherapy is infusion of tumor infiltrating Lymphocytes (TIL), with objective response rates of around 50% versus 19% for ipilimumab. As an Advanced Therapeutic Medicinal Products (ATMP), TIL is highly personalized and complex therapy. It requests substantial upfront investments from the hosp...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-018-4788-5
更新日期:2018-09-15 00:00:00
abstract:BACKGROUND:The prognostic value of rectal invasion is still unclear in stage IVA cervical cancer. The objective of this study is to evaluate patient outcome and prognostic factors in stage IVA cervical cancer treated with radiation therapy. METHODS:A retrospective review of the medical records of patients treated with...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2268-3
更新日期:2016-03-23 00:00:00
abstract:BACKGROUND:Platelet to Lymphocyte ratio (PLR) is thought to be associated with a worse outcome in multiple types of cancer. However, the prognostic significance of PLR has not been investigated in the prostate cancer (PCa) patients receiving hormonal therapy. The objective of this study was to determine the prognostic ...
journal_title:BMC cancer
pub_type: 杂志文章
doi:10.1186/s12885-016-2363-5
更新日期:2016-05-24 00:00:00
abstract:BACKGROUND:Median OS after surgery in curative intent for non-metastasized pancreas cancer ranges under study conditions from 17.9 months to 23.6 months. Tumor recurrence occurs locally, at distant sites (liver, peritoneum, lungs), or both. Observational and autopsy series report local recurrence rates of up to 87% eve...
journal_title:BMC cancer
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1186/1471-2407-14-411
更新日期:2014-06-07 00:00:00